Mutations

MAPT c.-17-19976G>A (rs242557)

Other Names: rs242557

Overview

Pathogenicity: Progressive Supranuclear Palsy : Likely Pathogenic, Corticobasal Degeneration : Likely Pathogenic, Frontotemporal Dementia : Likely Pathogenic, Alzheimer's Disease : Not Classified, Parkinson's Disease : Not Classified
Position: (GRCh38/hg38):Chr17:45942346 G>A
Position: (GRCh37/hg19):Chr17:44019712 G>A
dbSNP ID: rs242557
Coding/Non-Coding: Non-Coding
DNA Change: Allele
Expected RNA Consequence: Allele
Reference Isoform: Tau Isoform Tau-F (441 aa)
Genomic Region: Intron 1

Findings

This common intronic variant lies between the core promoter region of MAPT and the first coding exon. The A allele is found in the MAPT H1, but not H2, haplotype. More specifically, c.-17-19976 is part of the common H1c subhaplotype, for which it is sometimes used as a tag. Both H1c and c.-17-19976A are associated with an elevated risk of progressive supranuclear palsy, and possibly other primary tauopathies (see table below). Although some studies indicate c.-17-19976G>A may modify MAPT transcription and/or splicing (see Biological Effects below), these findings remain inconclusive and the degree to which other variants inherited with c.-17-19976G>A underlie or contribute to disease risk is unknown. Associations with other neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), have been examined, but results have been negative or inconsistent. 

The variant’s global frequency in gnomAD was 0.36, with the highest frequency in East Asians (0.56), in which G, rather than A is the minor allele, and lowest in Ashkenazi Jews (0.29) (gnomAD v4.1.0, Jul 2024). 

Progressive supranuclear palsy (PSP) | Other primary tauopathies | Alzheimer’s disease (AD) | Parkinson’s disease (PD) | Non-neurological effects | Biological effects

Progressive supranuclear palsy (PSP)
The A allele of c.-17-19976G>A is associated with an increased risk of PSP, at least in individuals of European ancestry (see table below). In addition to being a component of the H1c subhaplotype, it is part of the less common H1d, H1g, and H1o subhaplotypes—all associated with elevated PSP risk.

However, c.-17-19976G>A does not account for PSP-subhaplotype associations completely (Rademakers et al., 2005; Pittman et al., 2005; Höglinger et al., 2011; Jun 2011 news). A case-control study including 802 pathologically-confirmed PSP cases helped clarify this issue by showing that not all subhaplotypes with the A allele were linked to PSP (H1m), and conversely, three subhaplotypes that included the G allele (H1b, H1h, and H1r) were more frequent in PSP patients than controls (Heckman et al., 2019; Mar 2019 news). The authors suggested that associations observed for c.-17-19976G>A may be mostly driven by the H1c and H1d haplotypes.

Interestingly, copy numbers of duplications in the MAPT chromosomal region that affect chromosomal structure (α, β, and γ) may also shape how different subhaplotypes influence PSP risk. As reported in a preprint, the proportion of MAPT subhaplotypes associated with increased risk of PSP rose from 34 percent in a haplotype containing single β and γ sequences (H1β1γ1) to 77 percent in a haplotype with four γ duplications (H1β1γ4) (Wang et al., 2024).

Several studies have examined c.-17-19976G>A’s effects on the expression of PSP phenotypes, including neuropathological features, age at onset, and cognitive function. For example, the A allele was found to be associated with more severe PSP pathology, including phosphorylated tau-immunoreactive coiled bodies (Allen et al., 2016; Kouri et al., 2021) and tufted astrocytes (Allen et al., 2016). In addition, Rademakers and colleagues found the PSP association to be strongest in young patients, with the odds ratio approximately doubling with a reduction of 10 years in age (Rademakers et al., 2005). However, a joint analysis of PSP and corticobasal degeneration (CBD) cases did not identify an association of the variant with age at onset (Myers et al., 2007).  Surprisingly, one study found that PSP patients carrying the c.-17-19976A allele performed better than non-carriers on tests of general cognition, executive function, and attention (Gerstenecker et al., 2017). The authors hypothesized that c.-17-19976G>A’s effects may vary between PSP subtypes.

Other primary tauopathies
Several studies have also identified associations between c.-17-19976G>A and CBD (see table below). The link was first reported in a U.S. study of 44 pathologically confirmed CBD cases (Pittman et al., 2005), and subsequently confirmed in a study of 16 Spanish patients (Cruchaga et al., 2009). Several years later, a study including 219 pathologically confirmed cases and 3,750 controls from the U.S., also identified an association with CBD, but it was considered only “nominally significant” (Kouri et al., 2015). A more recent study, including 230 neuropathologically confirmed cases and 1,312 controls, suggests a situation similar to that of PSP in which associations are not consistent across H1 subhaplotypes (Valentino et al., 2024). The H1c and H1d subhaplotypes, which carry the c.-17-19976A allele, were associated with increased risk for CBD, but so was the H1b subhaplotype which carries the G allele.

The c.-17-19976G>A variant was also found to be associated with frontotemporal dementia (FTD), as revealed by a genome-wide analysis of 3,756 patients with sporadic FTD and 11,233 controls in which c.-17-19976G>A was used to tag the H1c suhaplotype (Manzoni et al., 2024). In contrast, no significant association was found between c.-17-19976G>A and the risk of Pick’s disease (Valentino et al., 2024).

A meta-analysis of six studies including 1,877 AD patients and 1,699 controls of Caucasian ancestry is among the few studies that has identified a positive association between c.-17-19976G>A and AD (Yuan et al., 2018). However, only the comparison of genotypes GG vs. GA+AA yielded a positive association, while analyses of GG+GA vs. AA, GG vs. AA, GG vs. GA, and GA vs. AA failed to reach statistical significance (allelic associations were not reported). Another study, of a Chinese Han cohort, reported a positive association, but it found the G allele, rather than the A allele, to be associated with AD (Liu et al., 2013). In this population, the G allele is the minor allele.

Although some studies have suggested the APOE4 allele is an important modifier of c.-17-19976G>A-mediated AD risk, results have been inconsistent. For example, one study identified a significant association between c.-17-19976A and AD only in APOE4 non-carriers (Myers et al., 2005), while two other studies identified an association only in APOE4 carriers (Abraham et al., 2009; Zhou and Wang 2017), with Abraham and colleagues' findings failing to survive correction for multiple comparisons (Abraham et al., 2009). A fourth study, in Chinese Han individuals, found significant associations with the G allele in both APOE4 carriers and non-carriers with a stronger association in APOE4 carriers (Liu et al., 2013).   
Associations involving the H1c haplotype and AD have been mixed as well. Myers and colleagues reported an association with AD (Myers et al., 2005; Myers et al., 2007), but others have not observed a significant link (e.g., Seto-Salvia 2011 21403021; Mukherjee et al., 2007; Abraham et al., 2009; Sánchez-Juan et al., 2019). The larger of these negative studies, including 4,124 Spanish AD cases and 3,290 controls, found the H1c subhaplotype to be nominally associated with AD risk, but the association failed to reach statistical significance after adjusting by population sub-structure (Sánchez-Juan et al., 2019).

Reports of associations between c.-17-19976G>A and AD endophenotypes have also yielded unclear results. A study including approximately 517 brain samples of AD patients from the U.S. found no association between the variant and AD pathology (Wider et al., 2012). A smaller study of AD cerebrospinal fluid (CSF) biomarkers in a Croatian cohort (113 AD patients), also failed to identify an association (Leko et al., 2018). However, a dose-dependent effect of c.-17-19976G>A on CSF tau levels was reported in another small Caucasian cohort (89 cases and controls; trend model: P=0.002, uncorrected; Laws et al., 2007). Also, two studies of cognitively healthy individuals suggested c.-17-19976A-associated phenotypes in brain regions vulnerable to AD: variations in cortical morphology in young healthy adults (Huang et al., 2023) and tau deposition in the hippocampi of non-demented elders (Shen et al., 2019).

Parkinson’s disease (PD)
c.-17-19976G>A does not appear to be an important contributor to PD risk (see table below) or PD endophenotypes. Indeed, the authors of a large study of the GEO-PD consortium concluded that the association they identified—not statistically significant after correction for multiple testing—was likely due to c.-17-19976G>A being in linkage disequilibrium with the causal variant rs1052553 (Elbaz et al., 2011).  Moreover, another study, including 1,218 Caucasian PD patients and 1,401 controls, also found no effect of c.-17-19976G>A on PD risk (Wider et al., 2010).

The few reports that have found significant associations involved moderate effects (see table below). For example, the authors of one meta-analysis study concluded c.-17-19976G>A was only “mildly associated” with PD risk in Caucasians (Zhang et al., 2017), while another detected a moderately significant association only when applying a genotypic recessive model in Caucasian (p=0.049) and Asian (p=0.046) populations (Chen et al., 2015). As shown in the table, allelic associations did not reach significance in this study. Moreover, an earlier study, using small cohorts, identified a weak association in the Finnish, but not the Greek or Taiwanese groups (Fung et al., 2006).

The association of PD with c.-17-19976G>A in the context of a subhaplotype is also unclear. De Silva and colleagues, for example, found no association between PD and the H1c haplotype (Vandrovcova et al., 2009). On the other hand, Tolosa and co-workers reported an H1 subhaplotype carrying the G allele as increased in PD (Ezquerra et al., 2011).

Regarding endophenotypes, c.-17-19976G>A was not associated with Lewy body pathology in evaluations of Caucasian PD autopsies (Wider et al., 2012), nor with PD age at onset in a Chinse cohort (Huang et al., 2015). Moreover, in a study assessing cognitive decline in PD, an association with the MAPT H1c subhaplotype was reported, but it did not reach statistical significance (Wang et al., 2016).

Non-neurological effects
Several studies have identified associations of c.-17-19976G>A with cardiac arrythmia, although effect sizes were small (GWAS Catalog, Aug 2024). A multi-ethnic genome-wide association study (GWAS) including over 500,000 participants revealed an association with atrial fibrillation (G allele: OR=1.04, CI=1.03-1.06, p=4x10-9; Roselli et al., 2018), as did a GWAS of over 77,000 individuals of European ancestry (A allele: β=0.041 unit decrease, p=2x10-11; Miyazawa et al., 2023). A third GWAS, including over 200,000 Japanese individuals, identified an association with cardiac arrythmia of unspecified type (A allele: OR=0.94 [CI=0.92-0.96], p=1x10-8; Ishigaki et al., 2020). Moreover, a study that intergrated data from GWAS, expression quantitative trait loci, and RNA/ATAC sequencing, identified c.-17-19976G>A as a candidate causal variant of atrial fibrillation (Leblanc et al., 2024).

Biological effect
c.-17-19976G>A lies within an evolutionarily conserved region 47kb downstream of the MAPT core promoter and 19 kb upstream of the first coding exon (Myers et al., 2007). It may be a functional variant, with the A allele boosting MAPT transcription and/or altering RNA splicing, but not all studies have detected significant effects.

In plasma, two GWASs identified significant associations between elevated tau levels and c.-17-19976A (Chen et al., 2017; Sarnowski et al., 2022). The larger of the two included nearly 15,000 individuals of European ancestry (β=0.2 unit increase, CI=0.18-0.22 p=9x10-143; Sarnowski et al., 2022).

Whether c.-17-19976A is associated with elevated tau levels in brain remains unclear. PCR analysis of post-mortem brain tissue from 88 Caucasians revealed a 3- to 4-fold increase in total transcript expression in both AD cases and controls that were H1c homozygotes compared with all other genotypes (Myers et al., 2007). Moreover, an expression GWAS (eGWAS) of tissue from 399 brains of Caucasians with various brain pathologies found significant increases in cerebellum and temporal cortex (Zou et al., 2012). However, in a follow-up study, the same group failed to identify significant associations between the H1c subhaplotype and brain tau levels, although they observed “suggestive associations” with c.-17-19976G>A that varied depending on the sequence of the probes used to detect MAPT mRNA (Allen et al., 2014). In addition, two studies using c.-17-19976G>A to tag the H1c haplotype—one examining post-mortem samples from 222 H1/H1 individuals (Trabzuni 2012) and the other from 39 H1/H2 individuals (Hayesmoore et al., 2009)—found no significant associations.

Several studies using cell-based reporter assays have identified c.-17-19976G>A-mediated effects on transcription. An early study using a luciferase reporter system showed that a 182-bp conserved binding site for transcription factors that includes c.-17-19976G>A, differentially influenced expression depending on the c.-17-19976G>A allele (Rademakers et al., 2005). A subsequent study, testing transcription of various constructs including the MAPT promoter along with upstream and downstream sequences in multiple cell types, concluded that the A allele of c.-17-19976G>A, in the context of subhaplotype H1c, was a key contributor to high MAPT promoter activity (Myers et al., 2007). A follow-up study from the same group identified proteins that bound to transcriptional repressor Region C, a conserved domain including c.-17-19976G>A (Anaya et al., 2011).

However, a global survey of gene expression across the brain found no evidence of c.-17-19976G>A affecting MAPT expression (Höglinger et al., 2011; June 2011 news). The authors identified several single nucleotide polymorphisms in the MAPT locus associated with the gene’s expression, but the associations did not survive correction for the H1/H2 inversion.

Studies that have examined whether c.-17-19976G>A affects the relative levels of spliced tau isoforms have yielded inconsistent results. Although Myers and colleagues found H1c homozygote brains had a large elevation of 4-repeat containing transcripts, which encode the tau isoform that accumulates in PSP, the sample size was small and results were highly variable (Myers et al., 2007). Another small study including 26 PSP cases and 53 controls also yielded inconsistent results (Majounie et al., 2013).

Of note, c.-17-19976G>A, or other variants inherited with c.-17-19976G>A, may affect the expression of genes beyond MAPT. For example, one study identified associations between c.-17-19976G>A and expression levels, as well as methylation patterns, of ADP-ribosylation factor-like (ARF-like) ARL17A and ARL17B (Allen et al., 2016). These two genes encode proteins involved in regulating membrane trafficking and vesicular transport.

This variant’s PHRED-scaled CADD score (19.90), which integrates diverse information in silico, nearly reached 20, a commonly used threshold to predict deleteriousness (CADD v.1.6, Aug 2024).

Table

Allelic Associations between c.-17-19976G>A and Neurodegenerative Disorders

Progressive Supranuclear Palsy

Disease Risk Allele(s) Risk allele Freq.
Cases | Controls		 N
Cases | CTRL		 Association Results Ancestry Reference
PSP A   2,568|7,014
(5 studies)a		 OR=1.96 [CI=1.71-2.25] Caucasian Zhang et al., 2017
PSP G 0.35|0.53 2,120|6,518 ORb=0.70 [CI=0.65-0.76]
p=9x10-18		 European Höglinger et al., 2011
PSP   0.42 1,718|1,441 βb=0.39
p=3.68 × 10–15		 European Wang et al., 2024
PSP     1,461|8,231
(3 studies)a		 OR=1.91
p=1.58x10-22		 European Chen et al., 2019
PSP A 0.57|0.45 513c|680 OR=1.6
[CI 1.2 - 2.0]
p < 0.001		 Caucasian
U.S., Canada		 Rademakers et al., 2005
PSP A 0.48 283|4,472 OR=1.93
p=9.03x10-13		 European Chen et al., 2019
PSP A 0.54 |0.31 238c|131 OR=2.36 [CI=1.71-3.26]
p=2.91x10-9		 U.S. Pittman et al., 2005
PSP A 0.48|0.36 83c|169 OR=1.82 [CI=1.21-2.73]
p=1.2x10-2		 White, U.K. Pittman et al., 2005
PSP G 0.53|0.66 127|190 OR=0.59 [CI=0.43-0.81]
p=0.003		 Spanish Cruchaga et al., 2009
PSP A 0.51|0.35 75|168 OR=1.9 [CI=1.3-2.8]
p=0.002		 Caucasian
British		 Williams et al., 2007

a Meta-analysis
b controlled for H1/H2
c pathologically confirmed / predominantly confirmed

Other Primary Taupathies

Disease

 Risk Allele(s) Risk allele Freq.
Cases | Controls		 N
Cases | CTRL		 Association Results Ancestry Reference
CBD A   2191|3,750 OR=1.57d
p=7.9x10-6		 U.S. Kouri et al., 2015
CBD A   60|321
(2 studies)a		 OR=2.51 [CI=1.66-3.78]
p(Q)=0.42		 Caucasian Zhang et al., 2017
CBD A 0.50|0.31 44c|131 OR=2.23 [CI=1.32-3.76]
p=2x10-3		 U.S. Pittman et al., 2005
CBD G 0.39|0.66 16|190  OR=0.33 [CI=0.15-0.74]
p=0.019		 Spanish Cruchaga et al., 2009
FTD A 0.48|0.45 3,756|11,233 Χ2
p = 5 × 10−3		 European Manzoni et al., 2024
Pick’s disease A 0.35|0.37 338|1,312 OR=0.94 [CI=0.79-1.12]
p=0.51		 European Valentino et al., 2024 (app 4)

a Meta-analysis
c pathologically confirmed / predominantly confirmed
d described as “nominally significant” by authors

Alzheimer's Disease

Disease

 Risk Allele(s) Risk allele Freq.
Cases | Controls		 N
Cases | CTRL		 Association Results Ancestry Reference
AD A 0.37 (cases) 14,666|17,532
(11 studies; 16 cohorts)a		 OR=1.03
[CI=1.00-1.06]
p=0.078		 Mixed: China, US, Europe Zhou and Wang 2017
AD A   12,912|14,203
(12 studies)a		 OR=1.02 [CI=0.94-1.12] Mixed Zhang et al., 2017
AD A   10 studiesa OR=1.02 [CI=0.98-1.06] Caucasian Zhang et al., 2017
AD A   2 studiesa OR=0.71 [CI=0.47-1.08] Asian Zhang et al., 2017
AD A 0.36|0.36 8,507|9,835 OR=1.00
[CI=0.95-1.05]
p=0.97		 European-American Allen et al., 2014
AD
(APOE4 carriers)		 A 0.39
(cases)		 1,157|645a
(3 studies)		 OR=1.24
[CI=1.08-1.43]
p=0.003		 Mixed: China, US, UK Zhou and Wang 2017
AD
(APOE4 non-carriers)		 A 0.42 (cases) 956|926a
(2 studies)		 OR=1.29
[CI=0.93-1.80]
p=0.13		 Mixed: China, US, UK Zhou and Wang 2017
AD A 0.38|0.37 1,082|1,239 p=0.067 White, U.K. Abraham et al., 2009
AD G 0.43 |0.39 796|796 OR=1.18
p = 0.026
[CI=1.02-1.35]
p=0.026		 Han Chinese Liu et al., 2013
AD
(APOE4 carriers)		 G 0.46|0.36 200|122 OR=1.51
[CI=1.09-2.09]
p=0.013		 Han Chinese Liu et al., 2013
AD A 0.38|0.34 655|380 OR=1.20
[CI=0.99-1.45]
p=0.068		 US, UK Myers et al., 2007
AD G 0.61|0.60 491|479 p=0.69 Caucasian
German		 Feulner et al., 2010
AD A 0.38|0.31 433|279 Χ2 analysis p=0.048 Caucasian, German Laws et al., 2007
AD A 0.37|0.34 428|475 OR=1.27 [CI=0.95–1.71]
p=0.11		 Caucasian
French		 Cousin et al., 2011
AD   0.36|0.37 361|358 Χ2=0.1 p=0.73 US Mukherjee et al., 2007
AD A 0.40|0.32 360|252 1.41
[CI=1.10-1.80]
p=0.007		 US, UK Myers et al., 2005
AD
(APOE4 carriers)		 A 0.39|0.33 240|66 1.31-
[CI=0.86-1.98]
p=0.21		 US, UK Myers et al., 2005
AD
(APOE4 non-carriers)		 A 0.42|0.32 120|186 1.16
[CI=1.11-2.10]
p=0.010		 US, UK Myers et al., 2005
AD A 0.51|0.65 180|106 p=0.020 Taiwanese Chang 2014

a Meta-analysis

Parkinson's Disease

Disease Risk Allele(s) Risk allele Freq.
Cases | Controls		 N
Cases | CTRL		 Association Results Ancestry Reference
PD A   10,662|25,557a
(23 studies)		 OR=1.02 [CI=0.98-1.06] Mixed Zhang et al., 2017
PD A   17 studiesa OR=1.06 [CI=1.01-1.12] Caucasian Zhang et al., 2017
PD A   6 studiesa OR=0.97 [CI=0.91-1.02] Asian Zhang et al., 2017
PD     6,840|5,856
3 studies		 OR=1.05
[CI=1.00-1.11] p=0.049		 Caucasian Chen et al., 2016
PD     1,373|1,075
2 studies		 OR=0.95
[CI=0.85-1.07]
p=0.422		 Asian Chen et al., 2016
PD G 0.40|0.41 1,261|830 p=0.71 Chinese Chen et al., 2016
PD A   5,302|4,161 OR=0.94
[CI=0.89-1.00] p=0.069		 Caucasian Elbaz et al., 2011
PD A 0.40|0.38 1,218|1,401 OR=0.92
CI: 0.82–1.03
p=0.16		 Caucasian
(Ireland, Norway, U.S.)		 Wider et al., 2010
PD A   242|215 OR=1.12
[CI=0.57-2.19]
p=0.73		 Greek Fung et al., 2006
PD A   147|136 OR=1.4
[CI=1.00-1.96]
p=0.04		 Finnish Fung et al., 2006
PD A   119|260 OR=1.23
[CI=0.88-1.71]
p=0.2		 Taiwanese Fung et al., 2006

a Meta-analysis

This table is meant to convey the range of results reported in the literature. As specific analyses, including co-variates, differ among studies, this information is not intended to be used for quantitative comparisons, and readers are encouraged to refer to the original papers. Thresholds for statistical significance were defined by the authors of each study. (Significant results are in bold.) Note that data from some cohorts may have contributed to multiple studies, so each row does not necessarily represent an independent dataset. While every effort was made to be accurate, readers should confirm any values that are critical for their applications.

Last Updated: 13 Sep 2024

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

  1. GWAS Fingers Tau and Other Genes for Parkinsonian Tauopathy
  2. Unequal: Some Tau Haplotypes Carry More Risk Than Others

Paper Citations

  1. Rademakers R, Melquist S, Cruts M, Theuns J, Del-Favero J, Poorkaj P, Baker M, Sleegers K, Crook R, De Pooter T, Bel Kacem S, Adamson J, Van den Bossche D, Van den Broeck M, Gass J, Corsmit E, De Rijk P, Thomas N, Engelborghs S, Heckman M, Litvan I, Crook J, De Deyn PP, Dickson D, Schellenberg GD, Van Broeckhoven C, Hutton ML. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005 Nov 1;14(21):3281-92. Epub 2005 Sep 29 PubMed.
  2. Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams D, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005 Nov;42(11):837-46. Epub 2005 Mar 25 PubMed.
  3. Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jun 19;43(7):699-705. PubMed.
  4. Heckman MG, Brennan RR, Labbé C, Soto AI, Koga S, DeTure MA, Murray ME, Petersen RC, Boeve BF, van Gerpen JA, Uitti RJ, Wszolek ZK, Rademakers R, Dickson DW, Ross OA. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurol. 2019 Jun 1;76(6):710-717. PubMed.
  5. Wang H, Chang TS, Dombroski BA, Si Y-Q, McLean C, Tucci A, Patil V, Valiente-Banuet L, Farrell K, Molina-porcel L, Rajput A, PaulDeDeyn P, LeBastard N, Gearing M, DonkerKaat L, VanSwieten JC, Dopper E, Ghetti BF, Newell KL, Troakes C, GdeYebenes J, Rabano-Gutierrez A, Meller T, Oertel WH, Respondek G, Stamelou M, Arzberger T, Roeber S, Muller U, Hopfner F, Pastor P, Brice A, Durr A, LeBer I, Beach TG, Serrano GE, Hazrati L-N, Litvan I, Rademakers R, Ross OA, Galasko D, Boxer AL, Mi. Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and MAPT Sub-haplotypes. 2024 Feb 28 10.1101/2024.02.26.24303379 (version 2) medRxiv.
  6. Allen M, Burgess JD, Ballard T, Serie D, Wang X, Younkin CS, Sun Z, Kouri N, Baheti S, Wang C, Carrasquillo MM, Nguyen T, Lincoln S, Malphrus K, Murray M, Golde TE, Price ND, Younkin SG, Schellenberg GD, Asmann Y, Ordog T, Crook J, Dickson D, Ertekin-Taner N. Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathol. 2016 Aug;132(2):197-211. Epub 2016 Apr 26 PubMed.
  7. Kouri N, Murray ME, Reddy JS, Serie DJ, Soto-Beasley A, Allen M, Carrasquillo MM, Wang X, Castanedes MC, Baker MC, Rademakers R, Uitti RJ, Graff-Radford NR, Wszolek ZK, Schellenberg GD, Crook JE, Ertekin-Taner N, Ross OA, Dickson DW. Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathol. 2021 May;141(5):667-680. Epub 2021 Feb 26 PubMed.
  8. Myers AJ, Pittman AM, Zhao AS, Rohrer K, Kaleem M, Marlowe L, Lees A, Leung D, McKeith IG, Perry RH, Morris CM, Trojanowski JQ, Clark C, Karlawish J, Arnold S, Forman MS, Van Deerlin V, de Silva R, Hardy J. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007 Mar;25(3):561-70. Epub 2006 Dec 15 PubMed.
  9. Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I. Genetic influences on cognition in progressive supranuclear palsy. Mov Disord. 2017 Dec;32(12):1764-1771. Epub 2017 Oct 27 PubMed.
  10. Cruchaga C, Vidal-Taboada JM, Ezquerra M, Lorenzo E, Martinez-Lage P, Blazquez M, Tolosa E, Iberian Atypical Parkinsonism Study Group Researchers, Pastor P. 5'-Upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiol Dis. 2009 Feb;33(2):164-70. Epub 2008 Nov 1 PubMed.
  11. Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NC, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JP, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 2015 Jun 16;6:7247. PubMed.
  12. Valentino RR, Scotton WJ, Roemer SF, Lashley T, Heckman MG, Shoai M, Martinez-Carrasco A, Tamvaka N, Walton RL, Baker MC, Macpherson HL, Real R, Soto-Beasley AI, Mok K, Revesz T, Christopher EA, DeTure M, Seeley WW, Lee EB, Frosch MP, Molina-Porcel L, Gefen T, Redding-Ochoa J, Ghetti B, Robinson AC, Kobylecki C, Rowe JB, Beach TG, Teich AF, Keith JL, Bodi I, Halliday GM, Gearing M, Arzberger T, Morris CM, White CL 3rd, Mechawar N, Boluda S, MacKenzie IR, McLean C, Cykowski MD, Wang SJ, Graff C, Nagra RM, Kovacs GG, Giaccone G, Neumann M, Ang LC, Carvalho A, Morris HR, Rademakers R, Hardy JA, Dickson DW, Rohrer JD, Ross OA, Pick's disease International Consortium. MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study. Lancet Neurol. 2024 May;23(5):487-499. PubMed.
  13. Manzoni C, Kia DA, Ferrari R, Leonenko G, Costa B, Saba V, Jabbari E, Tan MM, Albani D, Alvarez V, Alvarez I, Andreassen OA, Angiolillo A, Arighi A, Baker M, Benussi L, Bessi V, Binetti G, Blackburn DJ, Boada M, Boeve BF, Borrego-Ecija S, Borroni B, Bråthen G, Brooks WS, Bruni AC, Caroppo P, Bandres-Ciga S, Clarimon J, Colao R, Cruchaga C, Danek A, de Boer SC, de Rojas I, di Costanzo A, Dickson DW, Diehl-Schmid J, Dobson-Stone C, Dols-Icardo O, Donizetti A, Dopper E, Durante E, Ferrari C, Forloni G, Frangipane F, Fratiglioni L, Kramberger MG, Galimberti D, Gallucci M, García-González P, Ghidoni R, Giaccone G, Graff C, Graff-Radford NR, Grafman J, Halliday GM, Hernandez DG, Hjermind LE, Hodges JR, Holloway G, Huey ED, Illán-Gala I, Josephs KA, Knopman DS, Kristiansen M, Kwok JB, Leber I, Leonard HL, Libri I, Lleo A, Mackenzie IR, Madhan GK, Maletta R, Marquié M, Maver A, Menendez-Gonzalez M, Milan G, Miller BL, Morris CM, Morris HR, Nacmias B, Newton J, Nielsen JE, Nilsson C, Novelli V, Padovani A, Pal S, Pasquier F, Pastor P, Perneczky R, Peterlin B, Petersen RC, Piguet O, Pijnenburg YA, Puca AA, Rademakers R, Rainero I, Reus LM, Richardson AM, Riemenschneider M, Rogaeva E, Rogelj B, Rollinson S, Rosen H, Rossi G, Rowe JB, Rubino E, Ruiz A, Salvi E, Sanchez-Valle R, Sando SB, Santillo AF, Saxon JA, Schlachetzki JC, Scholz SW, Seelaar H, Seeley WW, Serpente M, Sorbi S, Sordon S, St George-Hyslop P, Thompson JC, Van Broeckhoven C, Van Deerlin VM, Van der Lee SJ, Van Swieten J, Tagliavini F, van der Zee J, Veronesi A, Vitale E, Waldo ML, Yokoyama JS, Nalls MA, Momeni P, Singleton AB, Hardy J, Escott-Price V. Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia. Am J Hum Genet. 2024 Jul 11;111(7):1316-1329. Epub 2024 Jun 17 PubMed.
  14. Allen M, Kachadoorian M, Quicksall Z, Zou F, Chai HS, Younkin C, Crook JE, Pankratz VS, Carrasquillo MM, Krishnan S, Nguyen T, Ma L, Malphrus K, Lincoln S, Bisceglio G, Kolbert CP, Jen J, Mukherjee S, Kauwe JK, Crane PK, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Parisi JE, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. Alzheimers Res Ther. 2014;6(4):39. Epub 2014 Jul 1 PubMed.
  15. Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC, Duckworth J, Leung D, Gibson A, Morris CM, de Silva R, Hardy J. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet. 2005 Aug 15;14(16):2399-404. Epub 2005 Jul 6 PubMed.
  16. Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease. BMC Genet. 2007 Jan 31;8:3. PubMed.
  17. Zhang CC, Zhu JX, Wan Y, Tan L, Wang HF, Yu JT, Tan L. Meta-analysis of the association between variants in MAPT and neurodegenerative diseases. Oncotarget. 2017 Jul 4;8(27):44994-45007. PubMed.
  18. Yuan H, Du L, Ge P, Wang X, Xia Q. Association of microtubule-associated protein tau gene polymorphisms with the risk of sporadic Alzheimer's disease: a meta-analysis. Int J Neurosci. 2018 Jun;128(6):577-585. PubMed.
  19. Liu QY, Yu JT, Miao D, Ma XY, Wang HF, Wang W, Tan L. An exploratory study on STX6, MOBP, MAPT, and EIF2AK3 and late-onset Alzheimer's disease. Neurobiol Aging. 2013 May;34(5):1519.e13-7. Epub 2012 Oct 30 PubMed.
  20. Abraham R, Sims R, Carroll L, Hollingworth P, O'Donovan MC, Williams J, Owen MJ. An association study of common variation at the MAPT locus with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2009 Dec 5;150B(8):1152-5. PubMed.
  21. Zhou F, Wang D. The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis. Oncotarget. 2017 Jun 27;8(26):43506-43520. PubMed.
  22. Sánchez-Juan P, Moreno S, de Rojas I, Hernández I, Valero S, Alegret M, Montrreal L, García González P, Lage C, López-García S, Rodrííguez-Rodríguez E, Orellana A, Tárraga L, Boada M, Ruiz A. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ε4 Non-carriers. Front Aging Neurosci. 2019;11:327. Epub 2019 Dec 4 PubMed.
  23. Wider C, Ross OA, Nishioka K, Heckman MG, Vilariño-Güell C, Jasinska-Myga B, Erketin-Taner N, Rademakers R, Graff-Radford NR, Mash DC, Papapetropoulos S, Duara R, Uchikado H, Wszolek ZK, Farrer MJ, Dickson DW. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):424-9. Epub 2012 Jan 30 PubMed.
  24. Babić Leko M, Willumsen N, Nikolac Perković M, Klepac N, Borovečki F, Hof PR, Sonicki Z, Pivac N, de Silva R, Šimić G. Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: A preliminary study in a Croatian cohort. Brain Behav. 2018 Nov;8(11):e01128. Epub 2018 Oct 17 PubMed.
  25. Laws SM, Friedrich P, Diehl-Schmid J, Müller J, Eisele T, Bäuml J, Förstl H, Kurz A, Riemenschneider M. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol Psychiatry. 2007 May;12(5):510-7. Epub 2006 Dec 19 PubMed.
  26. Huang W, Zeng J, Jia L, Zhu D, O'Brien J, Ritchie C, Shu N, Su L. Genetic risks of Alzheimer's by APOE and MAPT on cortical morphology in young healthy adults. Brain Commun. 2023;5(5):fcad234. Epub 2023 Sep 8 PubMed.
  27. Shen XN, Miao D, Li JQ, Tan CC, Cao XP, Tan L, Yu JT. MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders. Aging (Albany NY). 2019 Jan 31;11(3):874-884. PubMed.
  29. Wider C, Vilariño-Güell C, Jasinska-Myga B, Heckman MG, Soto-Ortolaza AI, Cobb SA, Aasly JO, Gibson JM, Lynch T, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA. Association of the MAPT locus with Parkinson's disease. Eur J Neurol. 2010 Mar;17(3):483-6. Epub 2009 Nov 12 PubMed.
  30. Chen Y, Cao B, Ou R, Chen X, Zhao B, Wei Q, Wu Y, Shang HF. Association analysis of the GRN  rs5848 and MAPT rs242557 polymorphisms in Parkinson's disease and multiple system atrophy: a large-scale population-based study and meta-analysis. Int J Neurosci. 2016 Oct;126(10):947-54. Epub 2015 Sep 17 PubMed.
  31. Fung HC, Xiromerisiou G, Gibbs JR, Wu YR, Eerola J, Gourbali V, Hellström O, Chen CM, Duckworth J, Papadimitriou A, Tienari PJ, Hadjigeorgiou GM, Hardy J, Singleton AB. Association of tau haplotype-tagging polymorphisms with Parkinson's disease in diverse ethnic Parkinson's disease cohorts. Neurodegener Dis. 2006;3(6):327-33. PubMed.
  32. Vandrovcova J, Pittman AM, Malzer E, Abou-Sleiman PM, Lees AJ, Wood NW, de Silva R. Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease. Neurobiol Aging. 2009 Sep;30(9):1477-82. Epub 2007 Dec 26 PubMed.
  33. Ezquerra M, Pastor P, Gaig C, Vidal-Taboada JM, Cruchaga C, Muñoz E, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E. Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. Neurobiol Aging. 2011 Mar;32(3):547.e11-6. Epub 2009 Oct 29 PubMed.
  34. Huang Y, Wang G, Rowe D, Wang Y, Kwok JB, Xiao Q, Mastaglia F, Liu J, Chen SD, Halliday G. SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians. Biomed Res Int. 2015;2015:135674. Epub 2015 Apr 15 PubMed.
  35. Wang G, Huang Y, Chen W, Chen S, Wang Y, Xiao Q, Liu J, Fung VS, Halliday G, Chen S. Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. Parkinsonism Relat Disord. 2016 Mar;24:89-94. Epub 2015 Dec 30 PubMed.
  37. Miyazawa K, Ito K, Ito M, Zou Z, Kubota M, Nomura S, Matsunaga H, Koyama S, Ieki H, Akiyama M, Koike Y, Kurosawa R, Yoshida H, Ozaki K, Onouchi Y, BioBank Japan Project, Takahashi A, Matsuda K, Murakami Y, Aburatani H, Kubo M, Momozawa Y, Terao C, Oki S, Akazawa H, Kamatani Y, Komuro I. Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk prediction. Nat Genet. 2023 Feb;55(2):187-197. Epub 2023 Jan 19 PubMed.
  38. Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nat Genet. 2020 Jul;52(7):669-679. Epub 2020 Jun 8 PubMed.
  40. Chen J, Yu JT, Wojta K, Wang HF, Zetterberg H, Blennow K, Yokoyama JS, Weiner MW, Kramer JH, Rosen H, Miller BL, Coppola G, Boxer AL, Alzheimer's Disease Neuroimaging Initiative. Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology. 2017 Feb 14;88(7):669-676. Epub 2017 Jan 18 PubMed.
  41. Sarnowski C, Ghanbari M, Bis JC, Logue M, Fornage M, Mishra A, Ahmad S, Beiser AS, Boerwinkle E, Bouteloup V, Chouraki V, Cupples LA, Damotte V, DeCarli CS, DeStefano AL, Djoussé L, Fohner AE, Franz CE, Kautz TF, Lambert JC, Lyons MJ, Mosley TH, Mukamal KJ, Pase MP, Portilla Fernandez EC, Rissman RA, Satizabal CL, Vasan RS, Yaqub A, Debette S, Dufouil C, Launer LJ, Kremen WS, Longstreth WT, Ikram MA, Seshadri S. Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels. Commun Biol. 2022 Apr 8;5(1):336. PubMed.
  42. Zou F, Chai HS, Younkin CS, Allen M, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Kouri N, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Alzheimer's Disease Genetics Consortium, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012;8(6):e1002707. Epub 2012 Jun 7 PubMed.
  43. Trabzuni D, Wray S, Vandrovcova J, Ramasamy A, Walker R, Smith C, Luk C, Gibbs JR, Dillman A, Hernandez DG, Arepalli S, Singleton AB, Cookson MR, Pittman AM, de Silva R, Weale ME, Hardy J, Ryten M. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet. 2012 Sep 15;21(18):4094-103. Epub 2012 Jun 20 PubMed.
  44. Hayesmoore JB, Bray NJ, Cross WC, Owen MJ, O'Donovan MC, Morris HR. The effect of age and the H1c MAPT haplotype on MAPT expression in human brain. Neurobiol Aging. 2009 Oct;30(10):1652-6. Epub 2008 Feb 13 PubMed.
  45. Anaya, Lees, de Silva. Tau Gene Promoter rs242557 and Allele-Specific Protein Binding. Transl Neurosci 2011 2(2):76-205.
  46. Majounie E, Cross W, Newsway V, Dillman A, Vandrovcova J, Morris CM, Nalls MA, Ferrucci L, Owen MJ, O'Donovan MC, Cookson MR, Singleton AB, de Silva R, Morris HR. Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging. 2013 Jul;34(7):1922.e7-1922.e12. Epub 2013 Feb 19 PubMed.
  47. Wang H, Chang TS, Dombroski BA, Cheng PL, Patil V, Valiente-Banuet L, Farrell K, Mclean C, Molina-Porcel L, Rajput A, De Deyn PP, Le Bastard N, Gearing M, Kaat LD, Van Swieten JC, Dopper E, Ghetti BF, Newell KL, Troakes C, de Yébenes JG, Rábano-Gutierrez A, Meller T, Oertel WH, Respondek G, Stamelou M, Arzberger T, Roeber S, Müller U, Hopfner F, Pastor P, Brice A, Durr A, Le Ber I, Beach TG, Serrano GE, Hazrati LN, Litvan I, Rademakers R, Ross OA, Galasko D, Boxer AL, Miller BL, Seeley WW, Van Deerlin VM, Lee EB, White CL 3rd, Morris H, de Silva R, Crary JF, Goate AM, Friedman JS, Leung YY, Coppola G, Naj AC, Wang LS, P. S. P. genetics study group, Dalgard C, Dickson DW, Höglinger GU, Schellenberg GD, Geschwind DH, Lee WP. Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy. Mol Neurodegener. 2024 Aug 16;19(1):61. PubMed. Correction.
  48. Chen Z, Chen JA, Shatunov A, Jones AR, Kravitz SN, Huang AY, Lawrence L, Lowe JK, Lewis CM, Payan CA, Lieb W, Franke A, Deloukas P, Amouyel P, Tzourio C, Dartigues JF, NNIPPS and BBBIPPS Study Groups, Ludolph A, Bensimon G, Leigh PN, Bronstein JM, Coppola G, Geschwind DH, Al-Chalabi A. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov Disord. 2019 Jul;34(7):1049-1059. Epub 2019 May 6 PubMed.
  49. Williams DR, Pittman AM, Revesz T, Lees AJ, de Silva R. Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Mov Disord. 2007 Apr 30;22(6):895-7. PubMed.
  50. Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, Kuhn KA, Krawczak M, Schreiber S, Nikolaus S, Förstl H, Kurz A, Riemenschneider M. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2010 Jul;15(7):756-66. PubMed.
  51. Cousin E, Macé S, Rocher C, Dib C, Muzard G, Hannequin D, Pradier L, Deleuze JF, Génin E, Brice A, Campion D. No replication of genetic association between candidate polymorphisms and Alzheimer's disease. Neurobiol Aging. 2011 Aug;32(8):1443-51. PubMed.
  52. Chang CW, Hsu WC, Pittman A, Wu YR, Hardy J, Fung HC. Structural study of the microtubule-associated protein tau locus of Alzheimer's disease in Taiwan. Biomed J. 2014 May-Jun;37(3):127-32. PubMed.

External Citations

  1. GWAS Catalog
  2. Wider et al., 2010

Further Reading

Papers

  1. Mateo I, Sánchez-Juan P, Rodríguez-Rodríguez E, Infante J, Vázquez-Higuera JL, García-Gorostiaga I, Berciano J, Combarros O. Synergistic effect of heme oxygenase-1 and tau genetic variants on Alzheimer's disease risk. Dement Geriatr Cogn Disord. 2008;26(4):339-42. PubMed.
  2. Tang X, Liu S, Cai J, Chen Q, Xu X, Mo C, Xu M, Mai TG, Li S, He H, Qin J, Zhang Z. Effects of Gene and Plasma Tau on Cognitive Impairment in Rural Chinese Population. Curr Alzheimer Res. 2021 Mar 24; PubMed.
  3. Caffrey TM, Joachim C, Paracchini S, Esiri MM, Wade-Martins R. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet. 2006 Dec 15;15(24):3529-37. PubMed.

Protein Diagram

Primary Papers

  1. Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams D, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005 Nov;42(11):837-46. Epub 2005 Mar 25 PubMed.
  2. Rademakers R, Melquist S, Cruts M, Theuns J, Del-Favero J, Poorkaj P, Baker M, Sleegers K, Crook R, De Pooter T, Bel Kacem S, Adamson J, Van den Bossche D, Van den Broeck M, Gass J, Corsmit E, De Rijk P, Thomas N, Engelborghs S, Heckman M, Litvan I, Crook J, De Deyn PP, Dickson D, Schellenberg GD, Van Broeckhoven C, Hutton ML. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005 Nov 1;14(21):3281-92. Epub 2005 Sep 29 PubMed.

Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.